ECM
APLT

ExodusPoint Capital Management’s Applied Therapeutics APLT Stock Holding History

ExodusPoint Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,457
Closed -$3K – 1511
2025
Q2 		$3K Buy
+10,457
New +$4.05K ﹤0.01% 1402
2024
Q2 		– Sell
-60,795
Closed -$413K – 1505
2024
Q1 		$413K Buy
+60,795
New +$273K ﹤0.01% 1181

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ExodusPoint Capital Management's APLT Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 10,457 shares — an estimated $3K sold.

ExodusPoint Capital Management first reported a position in APLT in Q1 2024 and held it in 2 quarters. The position peaked at $413K in Q1 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.

  • ExodusPoint Capital Management reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 10,457 Applied Therapeutics shares in Q3 2025, an estimated $3K.
  • ExodusPoint Capital Management first reported a position in Applied Therapeutics in Q1 2024 and held it in 2 quarters.
  • ExodusPoint Capital Management's Applied Therapeutics position peaked at $413K in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.